Thirty patients with radiolucent stones in a radiologically functioning gall bladder were treated for up to two years with a combination of Rowachol (one capsule twice daily), a mixture of cyclic monoterpenes, and chenodeoxycholic acid (7-0-10-5 mg/kg/day). The patients were not selected for body weight or size of stones. All complete dissolutions diagnosed by oral cholecystography were confirmed or refuted by ultrasound examination. Control of symptoms was excellent, only one patient withdrawing from the study because of persistent biliary pain. No evidence of hepatotoxicity was detected biochemically, and diarrhoea due to chenodeoxycholic acid was minimal at this dose. Stones disappeared completely in 11 patients (37%) within one year and in 15 (50%) within two years.
use of chenodeoxycholic acid for this purpose appeared in 1972.1 2 Since then ursodeoxycholic acid has also been widely used, and many reports have accumulated on the efficacy, safety, applicability, and possible mechanisms of action of treatment with bile acids. The clinical position has recently been reviewed3 4; confusion, however, remains, particularly regarding efficacy, as many earlier studies were uncontrolled and used widely differing doses and periods of treatment. In this context the recent publication of the results of the National Co-operative Gallstone Study made a valuable contribution. 5 Although criticised on the grounds of inadequate dosage of chenodeoxycholic acid,6 the study was a controlled investigation in a large series of patients who were selected only for the presence of radiolucent stones in a functioning gall bladder. As such, the study must now be the yardstick against which alternative regimens, including our own combinations of chenodeoxycholic acid with Rowachol (Rowa, Bantry, Ireland), are assessed.
Rowachol is an inexpensive preparation of six cyclic monoterpenes in olive oil and has choleretic' and spasmolytic' properties. Radiographically documented dissolution of gall stones during treatment with Rowachol has been described often,9-16 but its efficacy is inferior to that of full dose bile acids. In a previous study, however, by combining Rowachol 
Results
Treatment was generally well tolerated; only one patient noted appreciable diarrhoea, which was not sufficient to necessitate reduction in dosage. All patients remained within the study for the first six months, after which four were removed. Two of these four underwent surgery, one because her stones had enlarged during treatment and the other because he finally accepted that his stones were unlikely to dissolve (because of obesity and failure to reduce weight) and because he was having two or three attacks of biliary colic a year, the most BRITISH MEDICAL JOURNAL VOLUME 289 21 JULY 1984 recent of which had necessitated admission to hospital. The third patient to withdraw had ursodeoxycholic acid added to his regimen, and the fourth was an elderly diabetic woman who sustained a cerebral infarction. A further patient had an attack of cholecystitis at six months, which was successfully treated with antibiotics and glucagon infusion. She opted to continue treatment, and her stones had dissolved after a further six months.
After a year four more patients left the study and underwent surgery, one because of persistent non-function of the gall bladder, the three others as a result of advice given about the prognosis for dissolution on the grounds of the size of the stone, body weight, or progress so far, or a combination of these. Persistent symptoms had not been a problem in any of these four patients. At 18 months two patients were withdrawn and their treatment changed. One had abdominal discomfort of irritable bowel type, of which he had complained before starting treatment; he refused to continue with the regimen, even though his stones were showing progressive dissolution.
Only one patient received the treatment for two years without showing at least partial dissolution. She and a patient showing partial dissolution continued treatment beyond two years. Two further patients yielded negative results to cholecystography but positive results to ultrasound examinations after two years and continued treatment. At the end of the study one patient had only had treatment for a year but already showed partial dissolution. Complete dissolution occurred in 15 (50%) of our patients; in 11 (37 0%) it occurred within one year of starting treatment ( figure) . Table II shows the results of liver function tests in our patients. All individual changes were temporally related to attacks of colic or cholecystitis. 
Discussion
Although this was not a controlled study, it showed an encouraging response to treatment with a combination of Rowachol and below optimal doses of chenodeoxycholic acid in patients who were not selected in any way for features associated with good results of treatment. The importance of size of stone and body weight in determining response to treatment with bile acid is well recognised.20 Table I shows that six patients had stones over 1 5 cm in diameter and six patients were more than 130°of ideal weight for height.2' Stones dissolved in two obese patients (cases 7 and 9) receiving mean doses of chenodeoxycholic acid of less than 10 mg/kg/day in combination with Rowachol; such patients usually require 18-20 mg/kg/day to achieve desaturation of bile with chenodeoxycholic acid alone.22 If obese patients are excluded from the series, only 24 patients remain, in nine of whom (3800) stones dissolved completely within one year and in 13 (54%) within two years. Excluding patients with large (>1-5 cm) stones, there were 24 patients, in 11 of whom (4600) stones dissolved completely within one year and in 14 (58%) within two years. Exclusion of both groups leaves a total of 20 patients, in nine of whom (450o) stones dissolved completely within one year and in 12 (60%) within two years. These adjusted rates of dissolution are not substantially different from the response in the group as a whole; although the numbers are small, the response of the group as a whole suggests that when Rowachol Study.5 The occurrence in our series of complete dissolutions in 15 (500%) of our patients within two years compared with 13-5°' in the National Co-operative Gallstone Study5 is therefore striking. Although our patients may have derived some advantage from taking their chenodeoxycholic acid in a single night time dose,'28 which was tailored to body weight, '29 30 there are doubts about the absorption and bioavailability of large doses of chenodeoxycholic acid,3" and not everybody finds that doses related to weight are preferable to fixed ones." Thus our results suggest a useful adjuvant role for Rowachol. This would be best confirmed by a formal double blind study. Such a study is currently in progress in other centres, using ursodeoxycholic acid in full dosage with and without Rowachol.
At the dose of chenodeoxycholic acid used, diarrhoea was not a problem26 and patient tolerance was excellent. There was no evidence of drug toxicity, and control of symptoms was satisfactory, only one patient having to be referred for surgery because of continuing biliary pain. We therefore consider that a combination of Rowachol with medium dose (7-0-10-5 mg/kg/ day) treatment with chenodeoxycholic acid is a safe and acceptable alternative to full dose treatment with bile acid for radiolucent gall stones, which is likely to offer added benefits in the shape of good control of symptoms and reduced costs. One hundred and sixty nine patients admitted to hospital for stroke over 30 months were examined to see whether treating hypertension had influenced the incidence of cerebral haemorrhage and infarction. Seventy eight (46%) of them had normal blood pressure, 47 (28%) previously diagnosed hypertension for which they were receiving treatment, and 44 (26%) previously undiagnosed and untreated hypertension. Haemorrhagic stroke was commoner among patients with untreated hypertension, whereas infarction was commoner in patients with treated hypertension. Infarction and haemorrhage were equally prevalent in patients with normal blood pressure. Effective treatment in this population seemed to have had a substantially different impact on vascular disease, Introduction Hypertension is the most important known cause of strokes in men and women of all ages.' Despite a fall in the incidence of fatal strokes in some countries2 cerebrovascular disease still remains a major cause of death and disability, particularly among elderly people, though effective control of blood pressure has been confirmed to reduce the incidence of stroke in patients with moderate or severe hypertension3 and produce a dramatic improvement in prognosis among patients at highest risk. 4 Theoretically there could be two explanations for the continuing high incidence of strokes despite widespread availability of effective antihypertensive drugs. Strokes might be the result of untreated hypertension, or, alternatively, of hypertension for which treatment is, at least when started, partially or wholly ineffective. Epidemiological evidence suggests that hypertension remains an important treatable cause of death in the United Kingdom,5 and there can be little doubt that even patients at high risk go untreated. On the other hand, not all vascular pathological abnormalities associated with hypertension are reversed by control of blood pressure. Thus in most studies treatment for hypertension has had a disappointingly small effect on incidence of myocardial infarction.' 6 Strokes in patients
